Cargando…
Iliopsoas hematoma in patients with COVID-19 on low-molecular-weight heparin treatment
Patients with COVID-19 are at high risk of thromboembolic events; for this reason, the use of heparin is largely recommended but, in addition to thrombotic complications, bleeding is a significant cause of morbidity in patients with COVID-19. Idiopathic iliopsoas hematoma is a very rarely described...
Autores principales: | Sottilotta, Gianluca, Mangano, Carmelo, Basile, Rosa, Falcone, Carmela, Luise, Francesca, Megalizzi, Demetrio, Nicolò, Giovanna Maria, Oriana, Vincenzo, Piromalli, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161851/ https://www.ncbi.nlm.nih.gov/pubmed/34104443 http://dx.doi.org/10.1177/2050313X211016991 |
Ejemplares similares
-
Efficacy of Octocog Alfa (Advate) in a Child with Type 3 von Willebrand Disease and Alloantibodies
por: Sottilotta, Gianluca, et al.
Publicado: (2017) -
Use of Catridecacog in a patient with severe Factor XIII deficiency undergoing surgery
por: Sottilotta, Gianluca, et al.
Publicado: (2019) -
Iliopsoas hematoma associated with low-molecular-weight heparin use: A case report
por: Liu, Shangxiang, et al.
Publicado: (2020) -
Ultrasound therapy in iliopsoas hematoma
por: Kaya, Basak Bilir, et al.
Publicado: (2017) -
Heparin: Iliopsoas haematoma: case report
Publicado: (2021)